These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12920042)

  • 1. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
    Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
    Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA; Schrör K
    Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
    J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 13. Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide.
    Reiter R; Jilma-Stohlawetz P; Horvath M; Jilma B
    Transfusion; 2005 Mar; 45(3):420-6. PubMed ID: 15752161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
    J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
    Weber AA; Meila D; Jacobs C; Weber S; Kelm M; Strauer BE; Zotz RB; Scharf RE; Schrör K
    Thromb Res; 2002 Apr; 106(1):25-9. PubMed ID: 12165285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 17. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
    J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K
    Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.